Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
ABBV AbbVie Inc. weekly Stock Chart
ABBV [NYSE]
AbbVie Inc.
Healthcare | Drug Manufacturers - Major | USA
statements
IndexS&P 500 P/E26.94 EPS (ttm)2.78 Insider Own0.10% Shs Outstand1.50B Perf Week1.98%
Market Cap111.77B Forward P/E7.81 EPS next Y9.57 Insider Trans13.42% Shs Float1.48B Perf Month4.40%
Income4.18B PEG7.28 EPS next Q2.30 Inst Own72.10% Short Float4.12% Perf Quarter9.52%
Sales32.62B P/S3.43 EPS this Y4.80% Inst Trans1.83% Short Ratio7.08 Perf Half Y-4.14%
Book/sh-5.79 P/B- EPS next Y7.47% ROA6.80% Target Price86.55 Perf Year-16.18%
Cash/sh3.62 P/C20.64 EPS next 5Y3.70% ROE-58.90% 52W Range62.66 - 94.98 Perf YTD-18.92%
Dividend4.28 P/FCF16.74 EPS past 5Y7.60% ROI21.80% 52W High-20.98% Beta0.94
Dividend %5.73% Quick Ratio0.80 Sales past 5Y11.80% Gross Margin77.40% 52W Low19.77% ATR1.38
Employees30000 Current Ratio0.90 Sales Q/Q-0.30% Oper. Margin21.80% RSI (14)62.29 Volatility1.30% 1.84%
OptionableYes Debt/Eq- EPS Q/Q-60.60% Profit Margin12.50% Rel Volume0.05 Prev Close74.75
ShortableYes LT Debt/Eq- EarningsNov 01 BMO Payout148.90% Avg Volume8.59M Price75.05
Recom2.10 SMA201.92% SMA507.88% SMA200-1.35% Volume22,860 Change0.40%
Sep-26-19Upgrade Citigroup Neutral → Buy $87 → $90
Aug-20-19Upgrade Piper Jaffray Neutral → Overweight $80
Jun-27-19Upgrade Wolfe Research Underperform → Peer Perform
Jun-26-19Upgrade SVB Leerink Mkt Perform → Outperform $88
May-28-19Initiated Goldman Neutral
Apr-29-19Upgrade BMO Capital Markets Underperform → Market Perform
Mar-25-19Downgrade Argus Buy → Hold
Jan-23-19Initiated UBS Neutral $91
Jan-03-19Downgrade BofA/Merrill Buy → Neutral
Dec-26-18Initiated Standpoint Research Buy
Oct-22-18Reiterated SunTrust Buy $157 → $135
Oct-04-18Reiterated BofA/Merrill Buy $107 → $106
Jun-01-18Downgrade Piper Jaffray Overweight → Neutral
May-30-18Downgrade Credit Suisse Neutral → Underperform
Jan-30-18Reiterated Morgan Stanley Equal-Weight $99 → $131
Jan-29-18Downgrade Leerink Partners Outperform → Mkt Perform
Oct-30-17Reiterated Leerink Partners Outperform $108 → $107
Oct-02-17Upgrade Leerink Partners Mkt Perform → Outperform
Sep-25-17Downgrade UBS Buy → Neutral $79 → $92
Aug-17-17Initiated Evercore ISI Outperform $95
Oct-16-19 03:57PM  T Rowe Price Equity Income Fund's Top 5 Buys in the 3rd Quarter GuruFocus.com
03:01PM  Jim Cramer: Where Can You Still Get Some Growth and a Big Yield? TheStreet.com
09:10AM  Is AbbVie (ABBV) Stock Undervalued Right Now? Zacks
08:45AM  Here is Why Growth Investors Should Buy AbbVie (ABBV) Now Zacks
08:34AM  Top Ranked Momentum Stocks to Buy for October 16th Zacks
Oct-15-19 05:13PM  Reata Successfully Completes Neuromuscular Disorder Study Zacks
05:04PM  Allergan (AGN) Shareholders Approve Acquisition by AbbVie Zacks
04:13PM  How A Recently Reacquired Drug Added $1.8 Billion To This Biotech's Value Investor's Business Daily
12:21PM  AbbVie, Bristol-Myers Squibb Getting the Most From Workers GuruFocus.com
11:42AM  J&J (JNJ) Beats on Q3 Earnings as Sales Rise, Ups 2019 View Zacks
Oct-14-19 05:45PM  AbbVie (ABBV) Gains As Market Dips: What You Should Know Zacks
09:15AM  This is Why AbbVie (ABBV) is a Great Dividend Stock Zacks
Oct-11-19 04:27PM  Here Are Two Biotech Stocks To Watch As Earnings Season Kicks Off Investor's Business Daily
03:03PM  These battered biotech stocks are now buying opportunities as Elizabeth Warren climbs in the polls MarketWatch
08:37AM  Gilead Stock Is Up After Releasing Promising Drug Data Barrons.com
07:30AM  3 Big Stock Charts for Friday: AbbVie, Chubb and Applied Materials InvestorPlace
Oct-10-19 04:18PM  Why This Biotech Stock Was Bullish Enough To Relicense Its Own Drugs Investor's Business Daily
10:34AM  J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector Zacks
08:01AM  Top Ranked Income Stocks to Buy for October 10th Zacks
07:31AM  The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO Benzinga
Oct-09-19 05:37PM  Stocks To Buy: Is It Time To Buy Or Sell These Large-Cap Stocks? Investor's Business Daily
11:15AM  J&J Ordered by Philadelphia Jury to Pay $8B in Risperdal Case Zacks
11:10AM  Gilead (GILD) Files NDA for RA Candidate Filgotinib in Japan Zacks
02:01AM  AbbVie Announces New Data from its Dermatology Portfolio and Pipeline at the 28th European Academy of Dermatology and Venereology (EADV) Congress PR Newswire
Oct-08-19 05:54PM  Were Hedge Funds Right About Snapping Up AbbVie Inc (ABBV)? Insider Monkey
11:43AM  UPDATE 2-Humira, Rituxan top list of U.S. drugs with biggest price increases -report Reuters
08:30AM  AbbVie to Host Third-Quarter 2019 Earnings Conference Call PR Newswire
Oct-07-19 05:45PM  AbbVie (ABBV) Stock Moves -0.44%: What You Should Know Zacks
04:27PM  'Fast Money Halftime Report' Traders Advise Viewers On AbbVie, Home Depot And More Benzinga
01:30PM  3 Long-Term Dividend Payers Grant a High Forward Yield GuruFocus.com
05:55AM  Income Investors Should Know That AbbVie Inc. (NYSE:ABBV) Goes Ex-Dividend Soon Simply Wall St.
Oct-04-19 12:11PM  Medical stocks on the move: AbbVie, Arrowhead Pharmaceuticals and Zynex MarketWatch
10:04AM  5 Excellent GARP Picks Based on Discounted PEG Zacks
08:37AM  The Zacks Analyst Blog Highlights: Cintas, Air Products, Walmart, Target and AbbVie Zacks
Oct-03-19 04:17PM  Here Are 3 Notable Pharma Stocks That Could Top Third-Quarter Estimates Investor's Business Daily
04:11PM  10 Insider Trading Stocks: What Execs and Directors Are Buying Kiplinger
10:09AM  Novartis Reports Additional Data on Spondylitis Drug Cosentyx Zacks
09:00AM  AbbVie Stock Is Poised To Become A Top 5 Pharma But Should You Buy It? Investor's Business Daily
07:15AM  5 Dividend Aristocrats to Buy as October Sees a Shaky Start Zacks
Oct-02-19 09:29AM  Vertex Enters Into Collaboration With Privately-Held Ribometrix Zacks
09:20AM  The Zacks Analyst Blog Highlights: AbbVie, Starbucks, Phillips 66, Anheuser-Busch InBev and Square Zacks
07:34AM  Top Ranked Income Stocks to Buy for October 2nd Zacks
Oct-01-19 06:56PM  As Buyout Fever Grows, Alexion, Amarion and BioMarin Are Potential Targets GuruFocus.com
03:28PM  Top Stock Reports for AbbVie, Starbucks & Phillips 66 Zacks
09:11AM  AbbVie Falls 3% Investing.com
06:00AM  AbbVie- The Forest for the Trees MoneyShow
Sep-30-19 10:15PM  Top Marijuana Stocks That Pay Dividends Investopedia
05:45PM  AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know Zacks
11:00AM  Healthcare: Political Uncertainties Have Weighed on the Sector Morningstar
09:10AM  Is AbbVie (ABBV) a Great Value Stock Right Now? Zacks
09:00AM  AbbVie (ABBV) Upgraded to Buy: Here's What You Should Know Zacks
08:45AM  Here is Why Growth Investors Should Buy AbbVie (ABBV) Now Zacks
06:00AM  The 3 Best Health-Care Stocks This Month. And the Worst Barrons.com
Sep-28-19 02:40PM  Bulls And Bears Of The Week: Apple, Netflix, McDonald's, Visa, More Benzinga
Sep-27-19 05:38PM  AbbVie (ABBV) Gets FDA Nod for Label Expansion of HCV Drug Zacks
04:57PM  FTC requests AbbVie, Allergan for more information on $63 billion deal Reuters
04:16PM  Allergan and AbbVie Receive Second Request from Federal Trade Commission on Pending Transaction PR Newswire
04:15PM  AbbVie and Allergan Receive Second Request from Federal Trade Commission on Pending Transaction PR Newswire
09:15AM  This is Why AbbVie (ABBV) is a Great Dividend Stock Zacks
Sep-26-19 08:00PM  AbbVie Receives FDA Approval of MAVYRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis Across All Genotypes PR Newswire
01:46PM  Citi Bullish On AbbVie As Allergan Deal Provides An Earnings Floor Benzinga
01:37PM  6 Declining Stocks in Gurus' Portfolios GuruFocus.com
08:45AM  AbbVie Is Up After Another Analyst Reconsidered Its Allergan Acquisition and Upgraded the Stock Barrons.com
07:54AM  The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J Benzinga
07:49AM  [video]AbbVie Stock Gains on Citi Upgrade to Buy and Price-Target Boost TheStreet.com
06:35AM  AbbVie Rises 3% Investing.com
Sep-25-19 09:00AM  VENCLEXTA®, a treatment for chronic lymphocytic leukemia (CLL), now reimbursed across Western Canada CNW Group
Sep-24-19 01:38PM  quot;Healthyquot; Dividend Aristocrats: 6 Great Health-Care Dividends Kiplinger
Sep-23-19 05:45PM  AbbVie (ABBV) Gains As Market Dips: What You Should Know Zacks
01:22PM  AC Immune to Earn Milestone From Lilly for Alzheimer's Drug Zacks
03:01AM  AbbVie to Present New and Updated Data From 22 Abstracts, Including Two Late-Breaking Abstracts for ABBV-951 and DUODOPA® (levodopa/carbidopa intestinal gel), at the International Congress of Parkinson's Disease and Movement Disorders® PR Newswire
Sep-22-19 05:00PM  Notable Insider Buys In The Past Week: AbbVie, Kraft Heinz And More Benzinga
Sep-21-19 05:22PM  Top Insider Buys Highlight for the Week of Sept. 20 GuruFocus.com
09:56AM  Are Insiders Buying AbbVie Inc. (NYSE:ABBV) Stock? Simply Wall St.
Sep-20-19 01:10PM  Gilead, AbbVie Are Innovative, but May Be Underappreciated GuruFocus.com
07:00AM  AbbVie Stock Is Falling Because Investors Hate the Allergan Deal. The Vice Chairman Bought Up Shares. Barrons.com
Sep-19-19 10:55AM  The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, CSX, Danaher and ONEOK Zacks
Sep-18-19 01:30PM  Top Analyst Reports for AbbVie, Union Pacific & CSX Zacks
Sep-17-19 04:05PM  U.S. Senators urge FTC to scrutinize multi-billion dollar pharma mergers Reuters
11:05AM  Novartis Announces New Data on Spondylitis Drug Cosentyx Zacks
Sep-16-19 05:45PM  AbbVie (ABBV) Gains As Market Dips: What You Should Know Zacks
09:01AM  AbbVie Inc. -- Moody's assigns Baa2 to AbbVie's euro notes; stable outlook Moody's
Sep-13-19 03:29PM  Dividend Growth ETFs for Long Term Investors Zacks
11:08AM  Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland Zacks
Sep-12-19 06:22PM  Consumer groups, unions urge caution on $63 billion AbbVie deal for Allergan Reuters
05:46PM  Gilead Tops List of Most Innovative Drug Companies GuruFocus.com
04:09PM  Humira Sales Will Crash To $3 Billion Why AbbVie Stock Got An Upgrade Investor's Business Daily
11:47AM  Buy AbbVie Stock, Because Its Deal for Allergan Just Might Work, Analyst Says Barrons.com
10:54AM  AbbVie Stock Rises After UBS Upgrades To Buy TheStreet.com
Sep-11-19 09:32AM  4 Big Drugmakers Boasting Impressive Oncology Pipelines Zacks
09:15AM  Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio Zacks
Sep-10-19 10:55AM  10 Healthcare Stocks to Buy Despite the Headlines InvestorPlace
Sep-09-19 05:45PM  AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know Zacks
11:20AM  The Zacks Analyst Blog Highlights: Microsoft, Home Depot, AbbVie, Disney and Host Hotels Zacks
Sep-08-19 05:04PM  Weekly Top Insider Buys Highlight for the Week of Sept. 6 GuruFocus.com
07:00AM  3 Stocks to Buy With Dividends Yielding More Than 6% Motley Fool
Sep-06-19 01:56PM  Top Stock Reports for Microsoft, Home Depot & AbbVie Zacks
10:43AM  AbbVie Declares Quarterly Dividend PR Newswire
09:23AM  Can Copycats Take On $198 Billion In Blockbuster Biotech Sales? Investor's Business Daily
Sep-05-19 04:51PM  3 Special Situations Gurus Are Buying GuruFocus.com
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; and Calico Life Sciences LLC. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RICHMOND TIMOTHY J.EVP, Chief HR OfficerSep 27Sale75.0215,5151,163,8730Oct 01 05:52 PM
Schumacher Laura JVice ChairmanSep 16Buy70.4225,0001,760,523164,838Sep 18 04:25 PM
Donoghoe NicholasSVP, Enterprise InnovationAug 29Buy66.197,525498,05713,090Aug 30 04:08 PM
Stewart Jeffrey RyanSVP, US Commercial OperationsAug 16Buy64.4415,5521,002,16965,304Aug 20 04:16 PM
AUSTIN ROXANNE SDirectorAug 01Buy65.6625,0001,641,400117,114Aug 02 05:02 PM
AUSTIN ROXANNE SDirectorJul 31Buy66.0230,0001,980,69092,114Aug 02 05:02 PM
AUSTIN ROXANNE SDirectorJul 30Buy66.3510,000663,50062,114Jul 31 04:46 PM
Gosebruch Henry OEVP, Chief Strategy OfficerJul 29Buy67.2830,0002,018,38575,763Jul 31 04:46 PM
AUSTIN ROXANNE SDirectorJun 26Buy67.5011,500776,25052,114Jun 28 04:47 PM
CHASE WILLIAM JEVP, Finance & AdministrationJun 26Buy67.3030,4002,045,920169,552Jun 28 04:47 PM
RAPP EDWARD JDirectorJun 26Buy67.307,500504,75030,662Jun 28 04:48 PM
Durkin Brian LVP, ControllerMar 25Sale79.6947537,8539,121Mar 25 04:34 PM
Schumacher Laura JVice ChairmanMar 14Sale80.0025,0002,000,000139,838Mar 15 05:53 PM
SALEKI-GERHARDT AZITAEVP, OperationsMar 05Sale79.0315,7971,248,48093,312Mar 06 05:03 PM
Schumacher Laura JVice ChairmanDec 28Sale90.0025,0002,250,000134,322Jan 02 04:49 PM
CHASE WILLIAM JEVP, Finance & AdministrationDec 12Sale90.0060,0005,400,000104,863Dec 14 05:12 PM
GONZALEZ RICHARD AChairman of the Board and CEODec 11Sale88.7516,8501,495,438286,203Dec 13 04:56 PM
Schumacher Laura JExecutive Vice PresidentDec 04Option Exercise51.4294,1404,840,679192,398Dec 07 05:15 PM
Schumacher Laura JExecutive Vice PresidentDec 04Sale93.5894,1408,809,55298,258Dec 07 05:15 PM
Gosebruch Henry OEVP, Chief Strategy OfficerNov 29Sale90.1042,4503,824,94030,350Nov 30 05:22 PM
open in yahoo | open in reuters | open in google